Takara Bio Inc.
Japanese maker of genomics reagents and a gene/cell-therapy CDMO, now wholly owned by parent Takara Holdings.
On the record
Checkpoint: Definitive agreement to transfer cell-processing/CAR-T CDMO platform and TBI-1301 asset to S-RACMO
The call
Takara Bio is financially backstopped by its parent but is shrinking its own CDMO footprint while running losses in a market Thermo Fisher and Danaher already dominate.
Takara Bio makes lab chemicals and manufacturing services for gene and cell therapies, owned by a stable Japanese parent company. It is getting smaller, not bigger: it is selling off its most valuable piece (cell processing for CAR-T cancer treatments) to a sister company owned by Sumitomo, and it lost billions of yen in 2026. The real competitors, like Thermo Fisher and Lonza, are 100+ times bigger and have stronger brands, so Takara is outgunned; the one thing that could change this is if the parent pumps in cash and stops the selloff, but that does not look likely as of now.
Why
01
AI pressure: None apparent. No AI lab or agent is displacing Takara's reagent or CDMO business today; its risk is financial and scale, not automation. Could AI do the core job? Unlikely.
02
Bigger players: Thermo Fisher Scientific, Danaher/Cytiva, Merck KGaA/MilliporeSigma, Lonza. These firms already sell competing reagents and CDMO services at many times Takara's ¥45B scale across the same Japanese and global markets. Could a giant copy it? Probably.
03
What protects it. Takara Holdings now owns 100% and carries an A+ rating, guaranteeing funding even while the unit posts losses.
What would change this call
Final S-RACMO agreement (targeted Oct 2026) specifies whether CGCP GMP suites and TBI-1301 transfer fully to Sumitomo entity. Shows whether Takara Bio exits CAR-T/gene-therapy CDMO entirely or retains manufacturing capability.
FY2027 operating results (due ~May 2027) show return to operating profit or continued losses. Indicates whether the parent-backed restructuring is stabilizing the business or losses persist.
Takara Holdings publishes capital allocation or R&D funding commitment for Takara Bio's remaining reagents/spatial genomics units. Would show whether parent intends to grow remaining business or manage it for cash.
FY2027 operating results (due ~May 2027) show return to operating profit or continued losses. Indicates whether the parent-backed restructuring is stabilizing the business or losses persist.
Takara Holdings publishes capital allocation or R&D funding commitment for Takara Bio's remaining reagents/spatial genomics units. Would show whether parent intends to grow remaining business or manage it for cash.
Key numbers
- FY2026 guidance: net loss of about ¥9.0 billion
- Nine-month operating loss of ¥4.855 billion through Dec 2025
- Parent Takara Holdings owns 60.9% then completed full buyout by April 2026
Named risks
- Full exit from CDMO and CAR-T manufacturing via S-RACMO deal could leave company as subscale reagents-only player.
- Continued operating and net losses (9.619 billion yen nine month net loss through Dec 2025) with no clear profitability timeline.
- Loss of public listing removes market disclosure discipline and outside shareholder scrutiny after June 2026 delisting.
- Sub-scale position (about $300M revenue) against $42B plus incumbents like Thermo Fisher limits pricing power and R&D budget.
- Unconfirmed single-source claims about AI-driven process gains (MatrixBCG, April 2026) lack primary verification.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Thermo Fisher Scientific | losing to | Over $42B revenue vs Takara Bio's roughly 45B yen (about $300M) FY2025 sales, as of 2025-05-13 |
| Danaher (Cytiva) | losing to | Named dominant incumbent in cell and gene therapy tools market alongside Thermo Fisher, per 2025-10-13 industry survey |
| FUJIFILM | contesting | Japan-based rival operating its own cell and gene therapy CDMO unit, competing directly in home market |
| Sumitomo Pharma / S-RACMO | gaining on | Set to absorb Takara Bio's cell-processing and CAR-T CDMO platform via deal targeted for October 2026 |
| Lonza Group | losing to | Listed among larger global CDMO peers with greater scale in cell and gene therapy manufacturing services |
Questions people ask
- Is Takara Bio profitable in 2026?
- No. Takara Bio reported a nine month operating loss of 4.855 billion yen and a net loss of 9.619 billion yen for the period ended December 31, 2025, following a November 11, 2025 guidance cut projecting a full year operating loss of 4 billion yen and net loss of 9 billion yen.
- Is Takara Bio still a public company?
- No. Takara Holdings completed a tender offer for all remaining Takara Bio shares by April 6, 2026, and the shares were delisted from the Tokyo Stock Exchange around June 11 to 12, 2026 after a share consolidation, making Takara Bio a wholly owned subsidiary.
- Who owns Takara Bio now?
- Takara Holdings Inc. of Kyoto, which already held about 60.9 percent of shares as of March 2025, completed a tender offer in April 2026 and now owns Takara Bio outright following its June 2026 delisting from the Tokyo Stock Exchange.
- Who is Takara Bio's biggest competitor?
- Thermo Fisher Scientific, with reported revenue above 42 billion dollars, is cited as the dominant incumbent in cell and gene therapy tools and reagents alongside Danaher, Merck KGaA's MilliporeSigma, and Lonza, dwarfing Takara Bio's roughly 45 billion yen (about 300 million dollar) FY2025 sales.
- Could AI replace Takara Bio's CDMO business?
- Not directly. Takara Bio's cell and gene therapy manufacturing depends on GMP-certified facilities (CGCP I and II, with CGCP III underway) regulated under Japan's PMD Act and RM Safety Act as of September 2025, a licensing and physical-plant moat that AI software cannot replicate, though routine QC and bioinformatics add-ons remain exposed.
- Is Takara Bio selling off its gene therapy business?
- Takara Bio announced on July 21, 2026 a memorandum with Sumitomo Chemical, Sumitomo Pharma, and newly formed S-RACMO to transfer its cell-processing and CAR-T CDMO platform, with separate talks on its TBI-1301 gene therapy asset, and a definitive agreement targeted for October 2026.
Timeline
- 2026-07-21Signed MOU with Sumitomo Chemical, Sumitomo Pharma and S-RACMO to transfer CAR-T CDMO platform
- 2026-06-12Takara Bio delisted from Tokyo Stock Exchange after share consolidation
- 2026-04-08JCR upgraded Takara Bio issuer rating to A plus, aligned with parent Takara Holdings
- 2026-04-07Takara Holdings tender offer for remaining Takara Bio shares completed
- 2026-02-13Nine month results filed showing 4.855 billion yen operating loss, 9.619 billion yen net loss
- 2026-02-13Takara Holdings commenced tender offer to take Takara Bio private
- 2025-11-11FY2026 guidance cut to 4 billion yen operating loss, 9 billion yen net loss, dividend cancelled
- 2025-09-12Takara Bio Group published Long-Term Vision 2050
- 2025-05-13FY2025 results: net sales 45.039 billion yen, operating profit 2.263 billion yen
- 2025-01-15Acquired Curio Bioscience spatial genomics technology via Takara Bio USA
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Notice Regarding Results of the Tender Offer (2026-04-07)
- JPX delisting notice (2026-06-12)
- JCR rating announcement (2026-04-08)
- Consolidated Financial Results FY ended March 31, 2025 (2025-05-13)
- Notice Concerning Revisions to Financial Results Forecasts (2025-11-11)
- Consolidated Financial Results Nine Months Ended Dec 31, 2025 (2026-02-13)
- Takara Bio Revenue (Annual) Insights (2026-03-30)
- Takara Bio USA Acquires Curio Bioscience (2025-01-15)
- CDMO company profile document (2026-06-10)
- Takara Bio signs S-RACMO pact (2026-07-21)
- Notice Regarding Commencement of the Tender Offer (2026-02-13)
- Sustainability Index (2026-06-30)